MYC rs9642365: Bladder Cancer Susceptibility
rs9642365 is a non-coding single nucleotide polymorphism located on chromosome 8q24 in the genomic neighborhood of the MYC proto-oncogene. Genome-wide association studies have identified it as a common genetic marker linked to altered susceptibility to urinary bladder cancer. Carrying the risk allele is associated with a modest increase in population-level risk, though it does not directly cause cancer on its own.
What each genotype means
Typical bladder cancer risk
This genotype represents the common version of this genetic location. Research indicates that individuals with this profile do not carry the specific T-allele associated with increased susceptibility to bladder cancer in this region.
This is the most common genotype, found in the majority of individuals of European ancestry.
Slightly increased cancer susceptibility
Carrying one copy of the T-allele is associated with a statistically higher susceptibility to bladder cancer compared to those without the variant. This association is based on population-level data and does not mean you will develop the condition.
This genotype is carried by a significant portion of the population, consistent with the T-allele frequency of approximately 0.20 to 0.25 in European groups.
Elevated bladder cancer susceptibility
Individuals with two copies of the T-allele show a stronger statistical association with increased susceptibility to bladder cancer in studies of this 8q24 region. This finding is based on broad population research and should be viewed as one of many factors influencing health.
This genotype is the least common of the three, occurring at a frequency consistent with the known prevalence of the T-allele in European populations.
Genomic Location and Variant Characteristics
The single nucleotide polymorphism rs9642365 represents a common base substitution located on the long arm of human chromosome 8 at cytogenetic band 8q24. This chromosomal region is well-known in cancer genomics because it harbors several gene deserts and extended regulatory deserts that influence nearby oncogenes. Notably, rs9642365 does not alter an amino acid sequence within a protein; rather, it is a non-coding variation positioned in an intergenic or regulatory framework. Genomic variants in this region often function by altering enhancer-promoter looping or by disrupting transcription factor binding motifs, which can modulate the downstream expression of nearby target genes over substantial genomic distances.
The Role of the MYC Proto-Oncogene
The most prominent gene in the vicinity of rs9642365 is MYC, a well-characterized proto-oncogene encoding a multifunctional nuclear transcription factor. The MYC protein plays an essential role in cell proliferation, differentiation, cellular metabolism, and programmed cell death (apoptosis). Because MYC drives cell cycle progression and cell growth, its expression is tightly controlled in healthy tissue. Dysregulation or elevated expression of MYC has been implicated in the initiation and progression of various human malignancies. Non-coding variants across 8q24, such as rs9642365 and related markers, are hypothesized to alter long-range regulatory elements that govern MYC expression in epithelial tissues, including the urothelium.
Evidence for Bladder Cancer Susceptibility
Multiple genome-wide association studies (GWAS) and extensive meta-analyses have examined 8q24 variants in relation to urinary bladder cancer. The catalog notes that rs9642365 has a statistically significant association with bladder cancer susceptibility, classified with limited evidence strength in isolation due to the complex linkage disequilibrium architecture of the 8q24 region. In large-scale population cohorts, the risk-associated T allele correlates with a modest increase in the odds of developing bladder cancer compared to the baseline allele. However, this effect is typical of common polygenic susceptibility markers: it confers an incremental odds ratio rather than high, deterministic lifetime penetrance.
Population Frequency and Ancestry Context
Allele frequencies for rs9642365 vary across different global populations. In European reference cohorts, the risk allele T occurs at an estimated frequency between 0.20 and 0.25 (20% to 25%), meaning that heterozygous and homozygous genotypes are commonly observed in the general population. Across different continental ancestries, the exact background frequencies of variants across the 8q24 region differ, and the strength of correlation between rs9642365 and causal regulatory elements can shift depending on linkage disequilibrium patterns. Because most initial discovery cohorts for this specific marker were enriched for individuals of European descent, risk interpretations across non-European ancestral backgrounds require ongoing study.
Clinical Interpretation and Limitations
Understanding a person's genotype at rs9642365 provides informational insight into inherited baseline susceptibility, but it is not a diagnostic test. Bladder cancer is predominantly an acquired disease driven by environmental exposures and somatic genetic alterations. Established modifiable factors, most notably cigarette smoking and occupational chemical exposures, exert a substantially stronger influence on lifetime bladder cancer risk than any single common polymorphism. Genotypic results cannot confirm whether a person will develop bladder cancer or remain cancer-free, and testing for this variant alone does not alter standard medical management, cancer screening guidelines, or urological diagnostic pathways.
How common is this variant?
The risk allele T has an estimated frequency of approximately 0.20 to 0.25 across European populations, with corresponding genotypes commonly observed in general demographic surveys.
Frequently asked questions
Does having the rs9642365 risk allele mean I will develop bladder cancer?
No. Carrying the T allele represents only a modest statistical increase in susceptibility observed across large population studies. Bladder cancer risk is multifactorial, strongly influenced by environmental factors such as smoking, and most individuals carrying the risk allele never develop the disease.
What is the biological connection between rs9642365 and the MYC gene?
rs9642365 is located in a non-coding region on chromosome 8q24 near the MYC proto-oncogene. Researchers hypothesize that this locus sits within regulatory DNA elements that may modulate the transcription and expression of MYC in bladder tissue.
Can doctors use rs9642365 to screen for bladder cancer?
No, clinical guidelines do not recommend using rs9642365 or similar low-effect SNPs for routine cancer screening. Bladder cancer diagnosis relies on clinical signs such as hematuria (blood in urine), followed by cystoscopy and imaging evaluated by a urologist.
How common is the rs9642365 T allele in different populations?
In individuals of European descent, the T allele has an approximate frequency of 20% to 25%. Frequencies and linkage disequilibrium patterns can vary in other global ancestral groups, where further research is often needed to confirm effect sizes.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs9642365?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in MYC
This variant is a well-established risk factor for colorectal and prostate cancer susceptibility.
Non-coding variant in the 8q24 region near MYC associated with increased risk of colorectal and prostate cancers.
This variant is located in a gene desert near the MYC oncogene and is associated with an increased risk of colorectal and prostate cancers.
An intergenic variant at 7q31.1 demonstrated to associate with physician-diagnosed allergic conditions including allergic rhinitis.